On joining the board, Dr. Sonpavde said, “The primary focus of my career has been to develop new drugs and combinations for Gastroenterology CRO urinary bladder cancer as well as prostate and kidney cancer through clinical trials.
With new treatments like immunotherapies, antibody drug conjugates and target therapies, the field is accelerating towards improve cure rates. However, the clinical trials industry needs to be accelerating at that same pace, which is why I’m looking forward to working with Vial to ensure that Oncology trials are run with the utmost efficiency.”
Vial has worked closely with Oncology sponsors and investigators to develop a deep understanding of the nuances of clinical trials and the current pain points in running them. The result of that research is a tech-enable CRO offering that’s “Built for Sponsors.”
Nuremberg Code :
The new Gastroenterology CRO will leverage Vial’s streamline trial management system that integrates eSource, ePro, EDC, and CTMS into a seamless operating system. The CRO also offers additional best-in-class services to sponsors including more efficient study startup processes, a centralize pre-screening call center, and an unparallel approach to patient recruitment.
Dr. Sonpavde joins Dr. Arati Rao, Dr. Antoni Ribas, and Dr. Neeraj Agarwal on Vial’s Oncology CRO Scientific Advisory Board. Dr. Sonpavde is a leading urological oncologist with a specialty in bladder cancer.
He also has led translational projects and develop prognostic classifications and endpoints focus on bladder cancer. In addition to his roles at the Dana-Farber Cancer Institute and Harvard Medical School, Dr. Sonpavde is a member of the Genitourinary Committee of Southwest Oncology Group (SWOG) and the Bladder Cancer Task Force of the National Cancer Institute Genitourinary Steering Committee.
About Vial: Vial’s mission is to empower scientists to cure all human diseases. Vial has execute that vision by launching a next-generation Contract Research Organization (CRO) (with slate launches in Ophthalmology CRO, Oncology CRO, Gastroenterology CRO, and a Neurology CRO), a site network (Dermatology Clinical Trials, Ophthalmology Clinical Trials, Gastroenterology Clinical Trials.
Dr. James Lind’s Scurvy Trial :
Women’s Health Clinical Trials, Neurology Clinical Trials), and technology platform (VialConnect CTMS) to accelerate research. Vial has over 125 employees and is base in San Francisco, California, and has contribute to over 750 trials from Phase I through Phase IV. Follow Vial on LinkedIn for the latest company updates.
The Vial Dermatology CRO is thrille to welcome Jonathan Zung, PhD, as the newest addition to the Vial Scientific Advisory Board. Dr. Zung will support the Vial CRO team and their sponsors to further advance the field of dermatology clinical research and bring new therapies to the market.
The Vial Dermatology CRO was launch earlier this year to create a CRO Built for Sponsors. With over US$1 billion in technology products and over 25 years of experience managing top research sites – the Vial CRO and its team are power by the Vial Clinic Network of over 35 dermatology clinical research sites across the country, ensuring higher quality trials and faster execution.
Led by Betsey Zbyszynski as Head of Clinical Operations, Jason Shuris as Head of Sales, Janet DuBois, M.D. as Medical Director, and Justin Withers as Head of Dermatology, the CRO executive team brings 100+ years of combine dermatology clinical trial experience to Vial.
First Placebo :
To accomplish the Dermatology CRO vision, the Vial Scientific Advisory Board’s leading Dermatology KOLs will weigh in on clinical strategy, regulatory strategy, trial design and overall clinical development plan pathways. And ultimately, the Advisory Board will continue to drive Vial to build its networks, seek new challenges and reimagine trials.
“I’m excite to be joining Vial as an advisor to work with the team at Vial to improve clinical trials and advance Dermatology research infrastructure,” said Jonathan Zung.
Dr. Zung receive his B.S. in Chemistry at the Florida Institute of Technology and his Ph.D. in Analytical Chemistry at Emory University. Dr. Zung is an establish industry veteran, who brings over 30 years of global pharmaceutical development experience.
He is currently Chief Development Officer at Evelo Biosciences, a clinical stage biotechnology company developing a novel platform of orally deliver medicines acting on the small intestinal axis, SINTAX™.
Federal Food, Drug, and Cosmetic Act :
Prior to Evelo, he held executive leadership positions at WCG Clinical and Covance. At Covance, he serve as Group President of Clinical Development and Commercialization Services.
Dr. Zung has also held leadership roles of increasing responsibility at Bristol Myers Squibb, Pfizer, and UCB. At Bristol Myers Squibb, he led the Global Development Operations organization responsible for executing clinical trials across all therapeutic areas in over 40 countries.
Dr. Zung currently serves as an advisor to Saama Technologies and Syapse. He previously serve as a member and Chairman of CDISC.
Vial’s mission is to run clinical trials with faster execution and higher quality in order to bring new therapies to market. Vial has over 100 employees and is base in San Francisco, California.
Vial partners with Dermatologists and Ophthalmologists to support their research teams and has create a network of over 35 clinics that have contribute to over 750 trials. The clinic network runs trials from Phase I through Phase IV.
First Double-Blind Clinical Trial :
Clinical trials have been a part of the medical landscape for 275 years, creating opportunities for physicians to find viable treatments for a range of conditions. Along the way, there have been challenges but also triumphs. The clinical trials of decades – or even centuries – past brought the industry to where it is today.
Generally consider the first controll clinical trial in modern times, Dr. James Lind sought out a viable treatment for scurvy. He came face-to-face with the condition while working on a ship as a surgeon in 1747. Clinical Trials Day is held on May 20th every year to commemorate the day Dr. Lind began the trial.
Looking for a solution to avoid the high mortality rate or scurvy among sailors, he divide a group of those with scurvy into different groups and had each group follow a particular regimen. During this trial, he determine oranges and lemons (sources of vitamin C) gave the best result, creating a way to keep sailors safe from scurvy in the years to come.
Placebos are a powerful tool in a clinical trial setting, making it easier to assess the genuine impact of a drug. The term first ente the landscape in the early 1800s, including the 1811 edition of Hooper’s Medical Dictionary. However, the first known use of a placebo in a clinical trial didn’t occur until 1863, when Dr. Austin Flint coordinated a 13-person trial for rheumatism that involved a placebo.
First Randomized Curative :
After the Sulfa Craze of 1937 – where sulfonamide drugs were produce en masse without oversight, leading to 107 deaths relating to improperly prepared sulfa – the government replaced the Pure Food and Drug Act of 1906 with the Federal Food, Drug, and Cosmetic Act of 1938. It outlined requirements for new drugs to ensure safety before releasing them to the market.
Looking for a treatment for the common cold, the Medical Research Council (MRC) in the UK conduct the first double-blind clinical trial. A strict process ensure the treating physician and patient weren’t aware of whether the target treatment – patulin, a penicillium patulinum extract – was being administer. While the study itself didn’t prove patulin as an effective option, it did serve as a foundation for future double-blind clinical trials.
While randomization was initially introduce as a concept in 1923, it wasn’t until 1946 that the first randomized curative controlled clinical trial took place. The MRC conducted a streptomycin trial which was highly systematic in nature, using allocation concealment and objective monitoring approaches, improving the quality of the collected data. The strategy – while breaking from current norms – quickly became the framework for clinical trials moving forward.
During World War II, horrific, unscientific, and non-consensual experiments were perform on prisoners by the Nazis. While the Nuremberg Trials were underway, a separate “Doctor’s Trial” was held specifically for physicians who conduct said experiments.